Table 1.

Clinical Profiles at Baseline

	Buprenorphine/Naloxone	Methadone	Total
	(n=738)	(n=529)	(n=1,267)
Age, %
18–24	14.9	14.6	14.8
25–34	32.0	34.0	32.8
35–44	22.2	23.4	22.7
45–54	23.6	22.7	23.2
55+	7.3	5.3	6.5
Age, Mean (SD)	37.5 (11.2)	37.3 (10.9)	37.4 (11.1)
Female Gender, %	32.0	32.1	32.0
Race/Ethnicity, %
White	69.4	74.1	71.4
African American	8.5	8.9	8.7
Hispanic	13.4	10.0	12.0
Other	8.7	7.0	8.0
Clinic site location, %
West coast	70.3	67.3	69.1
East coast	29.8	32.7	30.9
# cigarettes smoked per day, %*
0	12.2	9.5	11.1
<10	28.6	26.8	27.9
11–20	44.9	46.1	45.4
21–30	11.9	12.1	12.0
31+	2.4	5.5	3.7
Days using opioids in past 30 days	26.8 (6.5)	26.7 (6.6)	26.8 (6.5)
Alcohol use, %	26.3	27.5	26.8
Cocaine positive UDS,1 %**	34.0	42.0	37.3
Amphetamine positive UDS, %	8.7	9.5	9.0
Cannabinoids positive UDS, %	25.3	21.4	23.7
Drug injection in past 30 days, %	68.3	69.3	68.7
SF-36 Physical Component Summary, Mean (SD)	49.5 (9.0)	49.2 (9.4)	49.4 (9.2)
SF-36 Mental Component Summary, Mean (SD)	39.4 (12.3)	38.8 (12.9)	39.1 (12.6)

^*p<0.05;

^**p<0.01

¹UDS=urine drug screen